Galectin-3 inhibition with modified citrus pectin in hypertension

Lau, E.S. (Emily S.); Liu, E. (Elizabeth); Paniagua, S.M. (Samantha M.); Sarma, A.A. (Amy A.); Zampierollo, G. (Giovanna); Lopez-Salazar, M.B. (María Begoña); Diez-Martinez, J. (Javier); Wang, T.J. (Thomas J.); Ho, J. E. (Jennifer H.)

Palabras clave :

Cardiac fibrosis
Galectin-3
Heart failure

Fecha de publicación :

2021

ISSN :

2452-302X

Nota:

This is an open access article under the CC BY-NC-ND license

Cita:

Lau, E. S.; Liu, E.; Paniagua, S. M.; et al. "Galectin-3 inhibition with modified citrus pectin in hypertension". JACC: Basic to Translational Science. 6 (1), 2021, 12 - 21

Resumen

We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

URI :

https://hdl.handle.net/10171/62042

DOI:

10.1016/j.jacbts.2020.10.006

Aparece en las colecciones:

DA - CIMA - Enfermedades cardiovasculares - Cardiopatía hipertensiva - Artículos de Revista
DA - CUN - Cirugía cardiaca - Artículos de revista

Ficheros en este ítem: